Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Total Non-Current Liabilities data on record, last reported at $7.4 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 51.06% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $7.4 million, up 51.06%, while the annual FY2024 figure was $4.6 million, 14.06% down from the prior year.
  • Total Non-Current Liabilities reached $7.4 million in Q3 2025 per PLX's latest filing, up from $4.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $46.5 million in Q4 2021 and bottomed at $4.4 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $18.9 million, with a median of $7.4 million recorded in 2021.
  • The widest YoY moves for Total Non-Current Liabilities: up 447.55% in 2021, down 88.77% in 2021.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $46.5 million in 2021, then decreased by 26.93% to $34.0 million in 2022, then tumbled by 84.31% to $5.3 million in 2023, then dropped by 14.06% to $4.6 million in 2024, then surged by 61.64% to $7.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $7.4 million in Q3 2025, $4.5 million in Q2 2025, and $4.4 million in Q1 2025.